Correction

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity (vol 36, pg 444.e1, 2019)

Journal

CANCER CELL
Volume 37, Issue 3, Pages 420-420

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2020.03.003

Keywords

-

Funding

  1. NCI NIH HHS [P01 CA078778, U54 CA224065, P30 CA016672, P50 CA070907, R01 CA190628] Funding Source: Medline

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Recommended

No Data Available
No Data Available